---
layout: default
title: Cinacalcet Hcl
parent: 僅模型預測 (L5)
nav_order: 161
evidence_level: L5
indication_count: 0
---

# Cinacalcet Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cinacalcet: Drug Repurposing Evaluation Report — No Predicted Indications Available

## One-Sentence Summary

Cinacalcet hydrochloride is a calcimimetic agent primarily used in the management of secondary hyperparathyroidism and hypercalcaemia. The TxGNN model has **not generated any predicted new indications** for this drug at this time. No clinical trial or literature evidence has been collated in the current evidence pack to support a repurposing direction.

## Quick Overview

| Item | Content |
|------|---------|
| Drug (INN) | Cinacalcet HCl |
| DrugBank ID | Not available |
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | **None** — no TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No model predictions or supporting studies) |
| UK Market Status | Not marketed (per evidence pack data) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, cinacalcet is a calcimimetic that acts as a positive allosteric modulator of the calcium-sensing receptor (CaSR) on parathyroid chief cells. By increasing the sensitivity of these receptors to extracellular calcium, cinacalcet suppresses parathyroid hormone (PTH) secretion. It is well established in the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, and for hypercalcaemia in parathyroid carcinoma or primary hyperparathyroidism.

However, the TxGNN model has not returned any predicted new indications for cinacalcet in the current analysis run. Without a specific repurposing hypothesis, it is not possible to assess mechanistic plausibility for a new therapeutic direction at this stage.

This absence of predictions may reflect the drug's highly specific mechanism (CaSR modulation), limited overlap with broader disease networks in the knowledge graph, or an issue with drug identity resolution (the DrugBank ID was not mapped in this evidence pack).

## Clinical Trial Evidence

Currently no related clinical trials registered in this evidence pack.

## Literature Evidence

Currently no related literature available in this evidence pack.

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

> **Note:** The evidence pack flagged the following data gaps as unresolved:
> - SmPC warnings and contraindications (severity: Blocking — prevents entry into Stage 1 safety screening)
> - Mechanism of action detail (severity: High — affects mechanistic relevance analysis)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted indications have been generated for cinacalcet, and critical safety and identity data gaps remain unresolved (including absence of DrugBank ID mapping and SmPC safety data). There is currently no repurposing hypothesis to evaluate.

**To proceed, the following is needed:**
- Resolve DrugBank ID mapping for cinacalcet HCl (expected: DB01012) and re-run TxGNN prediction pipeline
- Obtain and parse the SmPC to populate warnings, contraindications, and drug interaction data
- Confirm UK marketing authorisation status (note: cinacalcet is marketed in the UK under the brand name Mimpara — the evidence pack may contain a data-source discrepancy)
- Once predicted indications are generated, re-run the evidence collection pipeline (ClinicalTrials.gov, PubMed, ICTRP) to populate the clinical and literature evidence sections
- Re-evaluate at the next review cycle once the above gaps are addressed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

